In this exclusive MedPage Today video, Specht is joined via Zoom by study co-lead, Heather Jacene, MD, of Brigham and Women's ...

Pharmacokinetic (PK) - pharmacodynamic (PD) study of gemcitabine (G) in a randomised phase II trial of carboplatin (C) combined with G at standard rate infusion or fixed dose rate infusion in patients ...

Development and safety of a novel, irreversibly-binding PSMA-targeted prostate cancer radiodiagnostic. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not ...

What at least one investigator has been saying for nearly 2 decades is supported by a new study: 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) can provide important prognostic ...

Staging locally advanced breast cancer patients with 18 F-labeled fluorodeoxyglucose (FDG) PET-CT detected more distant metastases -- and thus reduced the number of patients who received combined ...

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of ...

PET scans were helpful in determining which patients with HER2-positive early breast cancer may be able to skip chemotherapy. Treating patients with HER2-positive early breast cancer based on positron ...

Positron emission tomography (PET) is a type of imaging scan that doctors might use when diagnosing and treating non-Hodgkin’s lymphoma (NHL). It can be useful for identifying and staging the cancer.